|
Display Options:
|
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
HALQUINOLS
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: Z7Z4BX535U |
| Molecule Type: Small molecule |
| Molecular Formula: C27H17Cl4N3O3 |
| Molecular Weight: 573.26 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Osteoarthritis
AMOBARBITAL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: GWH6IJ239E |
| Molecule Type: Small molecule |
| Molecular Formula: C11H18N2O3 |
| Molecular Weight: 226.28 |
| AlogP: 1.39 |
| PSA: 78.76 |
| HBD: 2.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
CHLORHEXIDINE HYDROCHLORIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: E64XL9U38K |
| Molecule Type: Small molecule |
| Molecular Formula: C22H32Cl4N10 |
| Molecular Weight: 578.38 |
| AlogP: 4.18 |
| PSA: 167.58 |
| HBD: 10.0 |
| HBA: |
| #RotB: 9.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MIDAZOLAM MALEATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 77520S18SE |
| Molecule Type: Small molecule |
| Molecular Formula: C22H17ClFN3O4 |
| Molecular Weight: 441.85 |
| AlogP: 4.32 |
| PSA: 30.18 |
| HBD: 0.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Obesity
DEXFENFLURAMINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: E35R3G56OV |
| Molecule Type: Small molecule |
| Molecular Formula: C12H16F3N |
| Molecular Weight: 231.26 |
| AlogP: 3.25 |
| PSA: 12.03 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
IODOXAMIC ACID
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: NS1Y283HW4 |
| Molecule Type: Small molecule |
| Molecular Formula: C26H26I6N2O10 |
| Molecular Weight: 1287.92 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder
BUTRIPTYLINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: Z22441975X |
| Molecule Type: Small molecule |
| Molecular Formula: C21H27N |
| Molecular Weight: 293.45 |
| AlogP: 4.5 |
| PSA: 3.24 |
| HBD: 0.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
DIPIPANONE HYDROCHLORIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 8VY00AJ0RL |
| Molecule Type: Small molecule |
| Molecular Formula: C24H32ClNO |
| Molecular Weight: 385.98 |
| AlogP: 5.22 |
| PSA: 20.31 |
| HBD: 0.0 |
| HBA: |
| #RotB: 7.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; anion channel positive allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
TETRAZEPAM
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: FO92091VP8 |
| Molecule Type: Small molecule |
| Molecular Formula: C16H17ClN2O |
| Molecular Weight: 288.78 |
| AlogP: 3.61 |
| PSA: 32.67 |
| HBD: 0.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Lung Diseases, Obstructive
ACEFYLLINE PIPERAZINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 12I91IOS6Z |
| Molecule Type: Small molecule |
| Molecular Formula: C22H30N10O8 |
| Molecular Weight: 562.54 |
| AlogP: -1.48 |
| PSA: 99.12 |
| HBD: 1.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
TECHNETIUM TC 99M MEDRONATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: X89XV46R07 |
| Molecule Type: Small molecule |
| Molecular Formula: CH6O6P2Tc |
| Molecular Weight: 274.91 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Rheumatic Diseases
FLUFENAMIC ACID
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 60GCX7Y6BH |
| Molecule Type: Small molecule |
| Molecular Formula: C14H10F3NO2 |
| Molecular Weight: 281.23 |
| AlogP: 4.15 |
| PSA: 49.33 |
| HBD: 2.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Digestive System Diseases
METHYLATROPINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 80719I460H |
| Molecule Type: Small molecule |
| Molecular Formula: C18H26NO3+ |
| Molecular Weight: 304.41 |
| AlogP: 2.08 |
| PSA: 46.53 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
SODIUM PERTECHNETATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: None |
| Molecule Type: Small molecule |
| Molecular Formula: NaO4Tc |
| Molecular Weight: 184.99 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Depressive Disorder; Diabetes Mellitus; Cognitive Dysfunction; Heart Failure; Premature Birth; Hernias, Diaphragmatic, Congenital; Parkinson Disease; Shock; Shock, Septic; Cardiovascular Diseases
DOPAMINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: VTD58H1Z2X |
| Molecule Type: Small molecule |
| Molecular Formula: C8H11NO2 |
| Molecular Weight: 153.18 |
| AlogP: 0.6 |
| PSA: 66.48 |
| HBD: 3.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Asperger Syndrome; Autistic Disorder; Head and Neck Neoplasms; Porokeratosis; Smith-Lemli-Opitz Syndrome
CHOLESTEROL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 97C5T2UQ7J |
| Molecule Type: Small molecule |
| Molecular Formula: C27H46O |
| Molecular Weight: 386.66 |
| AlogP: 7.39 |
| PSA: 20.23 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cough
ISOAMINILE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: R4823W2PQL |
| Molecule Type: Small molecule |
| Molecular Formula: C16H24N2 |
| Molecular Weight: 244.38 |
| AlogP: 3.44 |
| PSA: 27.03 |
| HBD: 0.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Delirium; Pain; Glaucoma
PHYSOSTIGMINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 9U1VM840SP |
| Molecule Type: Small molecule |
| Molecular Formula: C15H21N3O2 |
| Molecular Weight: 275.35 |
| AlogP: 1.77 |
| PSA: 44.81 |
| HBD: 1.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
DOPEXAMINE HYDROCHLORIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 0VN909S60Y |
| Molecule Type: Small molecule |
| Molecular Formula: C22H34Cl2N2O2 |
| Molecular Weight: 429.43 |
| AlogP: 3.62 |
| PSA: 64.52 |
| HBD: 4.0 |
| HBA: |
| #RotB: 13.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Attention Deficit Disorder with Hyperactivity
DEANOL ACEGLUMATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 2PP737Z523 |
| Molecule Type: Small molecule |
| Molecular Formula: C11H22N2O6 |
| Molecular Weight: 278.3 |
| AlogP: -0.56 |
| PSA: 103.7 |
| HBD: 3.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Leishmaniasis; Trypanosomiasis
ACETARSONE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 806529YU1N |
| Molecule Type: Small molecule |
| Molecular Formula: C8H10AsNO5 |
| Molecular Weight: 275.09 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Angiotensin-converting enzyme inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Cardiovascular Diseases
CILAZAPRIL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 8Q9454114Q |
| Molecule Type: Small molecule |
| Molecular Formula: C22H31N3O5 |
| Molecular Weight: 417.51 |
| AlogP: 1.6 |
| PSA: 99.18 |
| HBD: 2.0 |
| HBA: |
| #RotB: 8.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Coagulation factor XII activator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
BISMUTH SUBGALLATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: YIW503MI7V |
| Molecule Type: Small molecule |
| Molecular Formula: C7H5BiO6 |
| Molecular Weight: 394.09 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: ORAL
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: Myocardial Infarction; Myocardial Ischemia; Cataract; Crohn Disease; Macular Degeneration
BETA CAROTENE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 01YAE03M7J |
| Molecule Type: Small molecule |
| Molecular Formula: C40H56 |
| Molecular Weight: 536.89 |
| AlogP: 12.61 |
| PSA: 0.0 |
| HBD: 0.0 |
| HBA: |
| #RotB: 10.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Digestive System Diseases
PIPENZOLATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: RS3K5YXV34 |
| Molecule Type: Small molecule |
| Molecular Formula: C22H28NO3+ |
| Molecular Weight: 354.47 |
| AlogP: 3.09 |
| PSA: 46.53 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: INJECTION
STATUS: Approved
THERAPEUTIC AREA: OTHER
THERAPEUTIC INDICATION: HIV Infections
AMINOHIPPURATE SODIUM
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: SUO3KVS1O9 |
| Molecule Type: Small molecule |
| Molecular Formula: C9H9N2NaO3 |
| Molecular Weight: 216.17 |
| AlogP: 0.08 |
| PSA: 92.42 |
| HBD: 3.0 |
| HBA: |
| #RotB: 3.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
SULFIRAM
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 1XHL4Q8P7Y |
| Molecule Type: Small molecule |
| Molecular Formula: C10H20N2S3 |
| Molecular Weight: 264.49 |
| AlogP: 2.97 |
| PSA: 6.48 |
| HBD: 0.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Acetylcholinesterase inhibitor
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
CARBARIL
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: R890C8J3N1 |
| Molecule Type: Small molecule |
| Molecular Formula: C12H11NO2 |
| Molecular Weight: 201.22 |
| AlogP: 2.56 |
| PSA: 38.33 |
| HBD: 1.0 |
| HBA: |
| #RotB: 1.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MAGNESIUM ACETATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 0E95JZY48K |
| Molecule Type: Small molecule |
| Molecular Formula: C4H6MgO4 |
| Molecular Weight: 142.39 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
MAGNESIUM OROTATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: GI96W46M5A |
| Molecule Type: Small molecule |
| Molecular Formula: C10H6MgN4O8 |
| Molecular Weight: 334.48 |
| AlogP: None |
| PSA: None |
| HBD: None |
| HBA: |
| #RotB: None |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Investigational
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
SENNA
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: AK7JF626KX |
| Molecule Type: Small molecule |
| Molecular Formula: |
| Molecular Weight: |
| AlogP: |
| PSA: |
| HBD: |
| HBA: |
| #RotB: |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Histamine H1 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Hypersensitivity; Pruritus
THENALIDINE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 6U94N2D00F |
| Molecule Type: Small molecule |
| Molecular Formula: C17H22N2S |
| Molecular Weight: 286.44 |
| AlogP: 3.85 |
| PSA: 6.48 |
| HBD: 0.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: GABA-A receptor; agonist GABA site positive allosteric modulator
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Alcohol Drinking; Depressive Disorder, Major; Anxiety; Dementia; Depressive Disorder; Schizophrenia; Sleep Apnea, Obstructive; Sleep Initiation and Maintenance Disorders; Sleep Wake Disorders
ZOPICLONE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 03A5ORL08Q |
| Molecule Type: Small molecule |
| Molecular Formula: C17H17ClN6O3 |
| Molecular Weight: 388.82 |
| AlogP: 1.57 |
| PSA: 91.76 |
| HBD: 0.0 |
| HBA: |
| #RotB: 2.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Dopamine D2 receptor antagonist
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Anxiety; Dementia; Depressive Disorder; Schizophrenia; Psychotic Disorders
SULPIRIDE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: 7MNE9M8287 |
| Molecule Type: Small molecule |
| Molecular Formula: C15H23N3O4S |
| Molecular Weight: 341.43 |
| AlogP: 0.56 |
| PSA: 101.73 |
| HBD: 2.0 |
| HBA: |
| #RotB: 6.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Unknown
METHYLPREDNISOLONE ACEPONATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: ET54W9J4U2 |
| Molecule Type: Small molecule |
| Molecular Formula: C27H36O7 |
| Molecular Weight: 472.58 |
| AlogP: 3.34 |
| PSA: 106.97 |
| HBD: 1.0 |
| HBA: |
| #RotB: 5.0 |
| Source: |
MOLECULE TYPE: Small molecule
MECHANISMS OF ACTION: Unknown
ROUTE OF ADMINISTRATION: Unknown
STATUS: Approved
THERAPEUTIC AREA: Unknown
THERAPEUTIC INDICATION: Fever; Pain
BENORILATE
×| Maximum Phase: 4 |
| First Approval: None |
| UNII: W1QX9DV96G |
| Molecule Type: Small molecule |
| Molecular Formula: C17H15NO5 |
| Molecular Weight: 313.31 |
| AlogP: 2.79 |
| PSA: 81.7 |
| HBD: 1.0 |
| HBA: |
| #RotB: 4.0 |
| Source: |